You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Cancer Drug Lenalidomide May Increase Risk of Second Primary Malignancies

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000418924.37977.af
Drug Watch
Abstract

* The label of lenalidomide (Revlimid) now carries a warning that patients taking the drug for multiple myeloma have a heightened risk of new primary cancers.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.